135 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
11 Aug 20
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:05pm
and following the second quarter, three articles were published related to the Company’s efforts directed toward SARS-CoV-2:
In April, Nature Biotechnology … can be reduced to 5–6 months from a traditional timeline of 10–12 months.
In May, Nature published “Cross-neutralization of SARS-CoV-2 by a human
S-1
EX-10.1
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
, without limitation, all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys’, witness, or other … professional fees and related disbursements, and otherout-of-pocket costs of whatever nature, actually and reasonably incurred by Indemnitee
S-1
EX-10.42
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
, then the amount of each daily abatement of Base Rent shall only be proportionate to the nature and extent of the interruption of Tenant’s normal … or nature upon any doors or windows in the Premises, but excluding installation, removal or realignment of furniture systems (other than removal
DRS
EX-10.42
VIR
Vir Biotechnology Inc
27 Jun 19
Draft registration statement
12:00am
to the nature and extent of the interruption of Tenant’s normal operations or ability to use the Premises. The rights granted to Tenant under this paragraph shall … by or on behalf of Tenant, including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation, removal
S-1
EX-10.24
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
Organization; Authority; Binding Nature of Agreement; Subsidiaries; Management.
(a) The Company is a Swiss corporation limited by shares, duly formed … no, and has never had any, Subsidiary and the Company does not own any share capital of, or any equity interest of any nature in, any other Entity
DRS
EX-10.24
3x79oo5rktdiw
27 Jun 19
Draft registration statement
12:00am
DRS/A
EX-10.18
a0ly m3oh18l6zkk
7 Aug 19
Draft registration statement (amended)
12:00am
S-1
EX-10.18
qadhrs7jndy3pblu41
3 Sep 19
IPO registration
4:40pm
8-K
EX-99.1
vjqq1n4 dlim
7 Aug 20
Assignment and Novation Agreement
4:08pm
8-K
EX-99.2
axw8fjni9ovmv9pq
7 Aug 20
Assignment and Novation Agreement
4:08pm
8-K
EX-99.1
y6ld9jkx542vm9hrr
29 May 20
Vir Biotechnology and Biogen Execute Agreement to ManufactureSARS-CoV-2 Antibodies for PotentialCOVID-19 Treatment
4:06pm
8-K
EX-99.1
hdprne hl89fwbqp
19 Jun 20
Patent License Agreement
5:26pm
S-1
EX-10.44
8do0fw
3 Sep 19
IPO registration
4:40pm
DRS
EX-10.55
9jre4xlofy9lg
23 Jun 20
Draft registration statement
12:00am